The biggest clinical test to evaluate a new class of diabetes treatments has shown that AstraZeneca Farxiga can prevent heart and kidney risks for a wide range of patients, according to Reuters.
However, the drug related to a class of treatments known as SGLT2 inhibitors did not show significant statistical benefit for the prevention of cardiac attacks or stroke, even in patients with diagnosed cardiovascular disease. Diabetes is more at risk of heart problems, which make cardiovascular medicines benefiting from important attention from doctors and patients.
Stephen Wiviott of Brigham and the Boston Women's Hospital, senior researcher in this psychic study, said these findings were important in making a clear picture of SGLT2 drugs that have so far been treated for patients with diagnosed carcasses . AstraZeneca hopes that the new data will help extend the use of Farxiga to a wider range of patients. The main results of the Clinical Statement of Study, held on a cohort of 17,000 patients, were published in September, but details were disclosed on Saturday at the American Heart Society Annual Meeting and published at the same time at New England Journal of Medicine.
These results have shown that Farxiga reduces 27% of the risk of hospitals due to a heart problem, as well as the risk of kidney disease. Although two smaller studies involving competitive SGLT2 drugs have focused on patients with a diagnosis of heart disease, Wiviott said that the overall picture of the Declaration study shows that there is an extensive detention of heart attacks & The main benefit. "When we analyze the three studies, it is clear that the main advantage of this class of cardiovascular medicines is to reduce heart failure," said Wiviott.
For decades, diabetologists have focused mainly on reducing glucose levels in the blood at specific levels. But the assumption of diabetes to other issues, such as heart failure, where the five-year survival rate is 50% alone, indicates that a more holistic approach is needed, said Wiviott. "The current message is that we can reduce glucose levels to be as important as the proportion we do. We should choose medicines that improve patients' life expectancy, not only medicines that have the effectiveness of reducing blood glucose, "said doctor.
Farxiga competes with competing SGLT2 drugs, including Jardiance, produced by Eli Lilly and Boehringer Ingelheim, and Invokana Johnson & Johnson, who have already shown an increasing life expectancy for patients with diagnosed heart problems, known prevent secondary. As the AstraZeneca test has also evaluated patients without diagnostic cardiovascular disease, this study opens a wider market that includes basic prevention. The Declare study did not identify any increased risk of cancer, cuts, bladder or gangrene in patients who were treated with Farxiga, sometimes seen in patients who were treated with SGLT, but there was an increase in genital infections.